New combo shows promise for untreated lymphoma patients
NCT ID NCT01316523
First seen Nov 21, 2025 · Last updated May 22, 2026 · Updated 17 times
Summary
This study tested a combination of two drugs, lenalidomide and rituximab, in 30 adults with untreated slow-growing non-Hodgkin's lymphoma. Participants took lenalidomide daily for three weeks each month and received rituximab infusions weekly for four weeks. The goal was to see how many patients had their tumors shrink or disappear. The study was stopped early, but results help guide future treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN'S LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sutter Pacific Medical Foundation
Santa Rosa, California, 95403, United States
-
University of California Davis Cancer Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.